Intravenous 5% normal human immunoglobulin I.G. Vena in therapy of primary immunodeficiencies in children

I. N. Smirnova; Смирнова И. Н.; Yu. A. Rodina; Родина Ю. А.; E. V. Deripapa; Дерипапа Е. В.; S. A. Dibirova; Дибирова С. А.; A. Yu. Shcherbina; Щербина А. Ю.

doi:10.24287/1726-1708-2015-14-3-60-64

Intravenous 5% normal human immunoglobulin I.G. Vena in therapy of primary immunodeficiencies in children

Authors: Smirnova I.N.¹, Rodina Y.A.¹, Deripapa E.V.¹, Dibirova S.A.¹, Shcherbina A.Y.¹
Affiliations:
1. Federal Research Center of Pediatric Hematology, Oncology, and Immunology named after Dmitry Rogachev
Issue: Vol 14, No 3 (2015)
Pages: 60-64
Section: CLINICAL PHARMACOLOGY AND PHARMACOTHERAPY
Submitted: 19.09.2018
Published: 19.09.2015
URL: https://hemoncim.com/jour/article/view/113
DOI: https://doi.org/10.24287/1726-1708-2015-14-3-60-64
ID: 113

Cite item

Full Text

Abstract
About the authors
References
Supplementary files
Statistics

Abstract

Intravenous immunoglobulin G (IVIG) is the main modality of pathogenetic therapy for primary immunodeficiencies (PIDs). However, commercial IVIG preparations are not identical, and reliable clinical data are essential for the choice. We studied the efficacy and safety of 5% IVIG I.G. Vena® (“Kedrion C.p.A”, Italy) in the treatment of patients with PIDs aged 8 months to 13 years. The therapy maintained good trough serum IgG levels. The mean trough serum IgG level on previous therapy was7.3 ± 0.46 g/l, after 1 month of therapy with I.G. Vena - 6.8 ± 0.41 g/l, and after 2 months of therapy with I.G. Vena - 7.4 ± 0.46 g/l (p = 0.7 and 0.5 vs. the trough serum IgG level on previous therapy, respectively), which was associated with the absence of significant infectious episodes in patients with PIDs over 3 months of the study. No adverse reactions to the drug were recorded during the study. Hence, the results demonstrated the efficacy and safety of I.G. Vena in the treatment of children with PIDs.

Keywords

дети, первичные иммунодефицитные состояния, внутривенный иммуноглобулин, И.Г. Вена, претрансфузионный уровень IgG, эффективность, безопасность, children, primary immunodeficiencies, intravenous immunoglobulin, I.G. Vena, trough serum IgG level, efficiency, safety

References

Supplementary files

Supplementary Files

Action

1. JATS XML

Download

Username
Password
Remember me

Forgot password?	Register

Username
Password
Remember me

Forgot password?	Register

Intravenous 5% normal human immunoglobulin I.G. Vena in therapy of primary immunodeficiencies in children

Full Text

Abstract

Keywords

About the authors

I. N. Smirnova

Yu. A. Rodina

E. V. Deripapa

S. A. Dibirova

A. Yu. Shcherbina

References

Supplementary files